Cargando…
Immunotherapy: SAFETY AND EFFICACY OF SARS-COV-2-SPECIFIC T CELLS AS ADOPTIVE IMMUNOTHERAPY FOR HIGH-RISK COVID-19 PATIENTS: A PHASE I/II, RANDOMIZED CLINICAL TRIAL
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
International Society for Cell & Gene Therapy. Published by Elsevier Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035757/ http://dx.doi.org/10.1016/S1465-3249(22)00147-5 |
| _version_ | 1784693367891820544 |
|---|---|
| author | Papadopoulou, A. Karavalakis, G. Papadopoulou, E. Xochelli, A. Bousiou, Z. Vogiatzoglou, A. Papayanni, P.G. Georgakopoulou, A. Giannaki, M. Stavridou, F. Vallianou, I. Kammenou, M. Varsamoudi, E. Papadimitriou, V. Giannaki, C. Sileli, M. Stergiouda, Z. Stefanou, G. Kourlaba, G. Triantafyllidou, M. Siotou, E. Karaglani, A. Zotou, E. Chatzika, G. Boukla, A. Apostolou, D. Pitsiou, G. Morfesis, P. Bartzoudis, D. Imprialos, K. Karampatakis, T. Kapravelos, N. Bitzani, M. Theodorakopoulou, M. Serasli, E. Sakellari, I. Fylaktou, A. Tryfon, S. Anagnostopoulos, A. Yannaki, E. |
| author_facet | Papadopoulou, A. Karavalakis, G. Papadopoulou, E. Xochelli, A. Bousiou, Z. Vogiatzoglou, A. Papayanni, P.G. Georgakopoulou, A. Giannaki, M. Stavridou, F. Vallianou, I. Kammenou, M. Varsamoudi, E. Papadimitriou, V. Giannaki, C. Sileli, M. Stergiouda, Z. Stefanou, G. Kourlaba, G. Triantafyllidou, M. Siotou, E. Karaglani, A. Zotou, E. Chatzika, G. Boukla, A. Apostolou, D. Pitsiou, G. Morfesis, P. Bartzoudis, D. Imprialos, K. Karampatakis, T. Kapravelos, N. Bitzani, M. Theodorakopoulou, M. Serasli, E. Sakellari, I. Fylaktou, A. Tryfon, S. Anagnostopoulos, A. Yannaki, E. |
| author_sort | Papadopoulou, A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9035757 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | International Society for Cell & Gene Therapy. Published by Elsevier Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-90357572022-04-25 Immunotherapy: SAFETY AND EFFICACY OF SARS-COV-2-SPECIFIC T CELLS AS ADOPTIVE IMMUNOTHERAPY FOR HIGH-RISK COVID-19 PATIENTS: A PHASE I/II, RANDOMIZED CLINICAL TRIAL Papadopoulou, A. Karavalakis, G. Papadopoulou, E. Xochelli, A. Bousiou, Z. Vogiatzoglou, A. Papayanni, P.G. Georgakopoulou, A. Giannaki, M. Stavridou, F. Vallianou, I. Kammenou, M. Varsamoudi, E. Papadimitriou, V. Giannaki, C. Sileli, M. Stergiouda, Z. Stefanou, G. Kourlaba, G. Triantafyllidou, M. Siotou, E. Karaglani, A. Zotou, E. Chatzika, G. Boukla, A. Apostolou, D. Pitsiou, G. Morfesis, P. Bartzoudis, D. Imprialos, K. Karampatakis, T. Kapravelos, N. Bitzani, M. Theodorakopoulou, M. Serasli, E. Sakellari, I. Fylaktou, A. Tryfon, S. Anagnostopoulos, A. Yannaki, E. Cytotherapy Oral Abstracts International Society for Cell & Gene Therapy. Published by Elsevier Inc. 2022-05 2022-04-25 /pmc/articles/PMC9035757/ http://dx.doi.org/10.1016/S1465-3249(22)00147-5 Text en Copyright © 2022 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Oral Abstracts Papadopoulou, A. Karavalakis, G. Papadopoulou, E. Xochelli, A. Bousiou, Z. Vogiatzoglou, A. Papayanni, P.G. Georgakopoulou, A. Giannaki, M. Stavridou, F. Vallianou, I. Kammenou, M. Varsamoudi, E. Papadimitriou, V. Giannaki, C. Sileli, M. Stergiouda, Z. Stefanou, G. Kourlaba, G. Triantafyllidou, M. Siotou, E. Karaglani, A. Zotou, E. Chatzika, G. Boukla, A. Apostolou, D. Pitsiou, G. Morfesis, P. Bartzoudis, D. Imprialos, K. Karampatakis, T. Kapravelos, N. Bitzani, M. Theodorakopoulou, M. Serasli, E. Sakellari, I. Fylaktou, A. Tryfon, S. Anagnostopoulos, A. Yannaki, E. Immunotherapy: SAFETY AND EFFICACY OF SARS-COV-2-SPECIFIC T CELLS AS ADOPTIVE IMMUNOTHERAPY FOR HIGH-RISK COVID-19 PATIENTS: A PHASE I/II, RANDOMIZED CLINICAL TRIAL |
| title | Immunotherapy: SAFETY AND EFFICACY OF SARS-COV-2-SPECIFIC T CELLS AS ADOPTIVE IMMUNOTHERAPY FOR HIGH-RISK COVID-19 PATIENTS: A PHASE I/II, RANDOMIZED CLINICAL TRIAL |
| title_full | Immunotherapy: SAFETY AND EFFICACY OF SARS-COV-2-SPECIFIC T CELLS AS ADOPTIVE IMMUNOTHERAPY FOR HIGH-RISK COVID-19 PATIENTS: A PHASE I/II, RANDOMIZED CLINICAL TRIAL |
| title_fullStr | Immunotherapy: SAFETY AND EFFICACY OF SARS-COV-2-SPECIFIC T CELLS AS ADOPTIVE IMMUNOTHERAPY FOR HIGH-RISK COVID-19 PATIENTS: A PHASE I/II, RANDOMIZED CLINICAL TRIAL |
| title_full_unstemmed | Immunotherapy: SAFETY AND EFFICACY OF SARS-COV-2-SPECIFIC T CELLS AS ADOPTIVE IMMUNOTHERAPY FOR HIGH-RISK COVID-19 PATIENTS: A PHASE I/II, RANDOMIZED CLINICAL TRIAL |
| title_short | Immunotherapy: SAFETY AND EFFICACY OF SARS-COV-2-SPECIFIC T CELLS AS ADOPTIVE IMMUNOTHERAPY FOR HIGH-RISK COVID-19 PATIENTS: A PHASE I/II, RANDOMIZED CLINICAL TRIAL |
| title_sort | immunotherapy: safety and efficacy of sars-cov-2-specific t cells as adoptive immunotherapy for high-risk covid-19 patients: a phase i/ii, randomized clinical trial |
| topic | Oral Abstracts |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035757/ http://dx.doi.org/10.1016/S1465-3249(22)00147-5 |
| work_keys_str_mv | AT papadopouloua immunotherapysafetyandefficacyofsarscov2specifictcellsasadoptiveimmunotherapyforhighriskcovid19patientsaphaseiiirandomizedclinicaltrial AT karavalakisg immunotherapysafetyandefficacyofsarscov2specifictcellsasadoptiveimmunotherapyforhighriskcovid19patientsaphaseiiirandomizedclinicaltrial AT papadopouloue immunotherapysafetyandefficacyofsarscov2specifictcellsasadoptiveimmunotherapyforhighriskcovid19patientsaphaseiiirandomizedclinicaltrial AT xochellia immunotherapysafetyandefficacyofsarscov2specifictcellsasadoptiveimmunotherapyforhighriskcovid19patientsaphaseiiirandomizedclinicaltrial AT bousiouz immunotherapysafetyandefficacyofsarscov2specifictcellsasadoptiveimmunotherapyforhighriskcovid19patientsaphaseiiirandomizedclinicaltrial AT vogiatzogloua immunotherapysafetyandefficacyofsarscov2specifictcellsasadoptiveimmunotherapyforhighriskcovid19patientsaphaseiiirandomizedclinicaltrial AT papayannipg immunotherapysafetyandefficacyofsarscov2specifictcellsasadoptiveimmunotherapyforhighriskcovid19patientsaphaseiiirandomizedclinicaltrial AT georgakopouloua immunotherapysafetyandefficacyofsarscov2specifictcellsasadoptiveimmunotherapyforhighriskcovid19patientsaphaseiiirandomizedclinicaltrial AT giannakim immunotherapysafetyandefficacyofsarscov2specifictcellsasadoptiveimmunotherapyforhighriskcovid19patientsaphaseiiirandomizedclinicaltrial AT stavridouf immunotherapysafetyandefficacyofsarscov2specifictcellsasadoptiveimmunotherapyforhighriskcovid19patientsaphaseiiirandomizedclinicaltrial AT vallianoui immunotherapysafetyandefficacyofsarscov2specifictcellsasadoptiveimmunotherapyforhighriskcovid19patientsaphaseiiirandomizedclinicaltrial AT kammenoum immunotherapysafetyandefficacyofsarscov2specifictcellsasadoptiveimmunotherapyforhighriskcovid19patientsaphaseiiirandomizedclinicaltrial AT varsamoudie immunotherapysafetyandefficacyofsarscov2specifictcellsasadoptiveimmunotherapyforhighriskcovid19patientsaphaseiiirandomizedclinicaltrial AT papadimitriouv immunotherapysafetyandefficacyofsarscov2specifictcellsasadoptiveimmunotherapyforhighriskcovid19patientsaphaseiiirandomizedclinicaltrial AT giannakic immunotherapysafetyandefficacyofsarscov2specifictcellsasadoptiveimmunotherapyforhighriskcovid19patientsaphaseiiirandomizedclinicaltrial AT silelim immunotherapysafetyandefficacyofsarscov2specifictcellsasadoptiveimmunotherapyforhighriskcovid19patientsaphaseiiirandomizedclinicaltrial AT stergioudaz immunotherapysafetyandefficacyofsarscov2specifictcellsasadoptiveimmunotherapyforhighriskcovid19patientsaphaseiiirandomizedclinicaltrial AT stefanoug immunotherapysafetyandefficacyofsarscov2specifictcellsasadoptiveimmunotherapyforhighriskcovid19patientsaphaseiiirandomizedclinicaltrial AT kourlabag immunotherapysafetyandefficacyofsarscov2specifictcellsasadoptiveimmunotherapyforhighriskcovid19patientsaphaseiiirandomizedclinicaltrial AT triantafyllidoum immunotherapysafetyandefficacyofsarscov2specifictcellsasadoptiveimmunotherapyforhighriskcovid19patientsaphaseiiirandomizedclinicaltrial AT siotoue immunotherapysafetyandefficacyofsarscov2specifictcellsasadoptiveimmunotherapyforhighriskcovid19patientsaphaseiiirandomizedclinicaltrial AT karaglania immunotherapysafetyandefficacyofsarscov2specifictcellsasadoptiveimmunotherapyforhighriskcovid19patientsaphaseiiirandomizedclinicaltrial AT zotoue immunotherapysafetyandefficacyofsarscov2specifictcellsasadoptiveimmunotherapyforhighriskcovid19patientsaphaseiiirandomizedclinicaltrial AT chatzikag immunotherapysafetyandefficacyofsarscov2specifictcellsasadoptiveimmunotherapyforhighriskcovid19patientsaphaseiiirandomizedclinicaltrial AT bouklaa immunotherapysafetyandefficacyofsarscov2specifictcellsasadoptiveimmunotherapyforhighriskcovid19patientsaphaseiiirandomizedclinicaltrial AT apostoloud immunotherapysafetyandefficacyofsarscov2specifictcellsasadoptiveimmunotherapyforhighriskcovid19patientsaphaseiiirandomizedclinicaltrial AT pitsioug immunotherapysafetyandefficacyofsarscov2specifictcellsasadoptiveimmunotherapyforhighriskcovid19patientsaphaseiiirandomizedclinicaltrial AT morfesisp immunotherapysafetyandefficacyofsarscov2specifictcellsasadoptiveimmunotherapyforhighriskcovid19patientsaphaseiiirandomizedclinicaltrial AT bartzoudisd immunotherapysafetyandefficacyofsarscov2specifictcellsasadoptiveimmunotherapyforhighriskcovid19patientsaphaseiiirandomizedclinicaltrial AT imprialosk immunotherapysafetyandefficacyofsarscov2specifictcellsasadoptiveimmunotherapyforhighriskcovid19patientsaphaseiiirandomizedclinicaltrial AT karampatakist immunotherapysafetyandefficacyofsarscov2specifictcellsasadoptiveimmunotherapyforhighriskcovid19patientsaphaseiiirandomizedclinicaltrial AT kapravelosn immunotherapysafetyandefficacyofsarscov2specifictcellsasadoptiveimmunotherapyforhighriskcovid19patientsaphaseiiirandomizedclinicaltrial AT bitzanim immunotherapysafetyandefficacyofsarscov2specifictcellsasadoptiveimmunotherapyforhighriskcovid19patientsaphaseiiirandomizedclinicaltrial AT theodorakopouloum immunotherapysafetyandefficacyofsarscov2specifictcellsasadoptiveimmunotherapyforhighriskcovid19patientsaphaseiiirandomizedclinicaltrial AT seraslie immunotherapysafetyandefficacyofsarscov2specifictcellsasadoptiveimmunotherapyforhighriskcovid19patientsaphaseiiirandomizedclinicaltrial AT sakellarii immunotherapysafetyandefficacyofsarscov2specifictcellsasadoptiveimmunotherapyforhighriskcovid19patientsaphaseiiirandomizedclinicaltrial AT fylaktoua immunotherapysafetyandefficacyofsarscov2specifictcellsasadoptiveimmunotherapyforhighriskcovid19patientsaphaseiiirandomizedclinicaltrial AT tryfons immunotherapysafetyandefficacyofsarscov2specifictcellsasadoptiveimmunotherapyforhighriskcovid19patientsaphaseiiirandomizedclinicaltrial AT anagnostopoulosa immunotherapysafetyandefficacyofsarscov2specifictcellsasadoptiveimmunotherapyforhighriskcovid19patientsaphaseiiirandomizedclinicaltrial AT yannakie immunotherapysafetyandefficacyofsarscov2specifictcellsasadoptiveimmunotherapyforhighriskcovid19patientsaphaseiiirandomizedclinicaltrial |